{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:38:01Z","timestamp":1792687081812,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s11060-026-05835-6","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:11Z","timestamp":1792683971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MEK inhibitors in NF1-associated high-grade glioma: partial responses and outcomes from a single-institution cohort and literature review"],"prefix":"10.1007","volume":"180","author":[{"given":"Ming-Chun","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen H.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqsa","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie R.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Slopis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kamiya-Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"5835_CR1","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH et al (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004. https:\/\/doi.org\/10.1038\/nrdp.2017.4","journal-title":"Nat Rev Dis Primers"},{"key":"5835_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00401-022-02478-5","volume":"144","author":"CHG Lucas","year":"2022","unstructured":"Lucas CHG, Sloan EA, Gupta R et al (2022) Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol 144:747\u2013765. https:\/\/doi.org\/10.1007\/s00401-022-02478-5","journal-title":"Acta Neuropathol"},{"key":"5835_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","volume":"22","author":"RJ Packer","year":"2020","unstructured":"Packer RJ, Iavarone A, Jones DTW et al (2020) Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro Oncol 22:773\u2013784. https:\/\/doi.org\/10.1093\/neuonc\/noaa036","journal-title":"Neuro Oncol"},{"key":"5835_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo F, Ceccarelli M, Tala GL et al (2019) The molecular landscape of glioma in patients with neurofibromatosis 1. Nat Med 25:176\u2013187. https:\/\/doi.org\/10.1038\/s41591-018-0263-8","journal-title":"Nat Med"},{"key":"5835_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00401-021-02276-5","volume":"141","author":"MJ Fisher","year":"2021","unstructured":"Fisher MJ, Jones DTW, Li Y et al (2021) Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). Acta Neuropathol 141:605\u2013617. https:\/\/doi.org\/10.1007\/s00401-021-02276-5","journal-title":"Acta Neuropathol"},{"key":"5835_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1101\/gr.142604.112","volume":"23","author":"DH Gutmann","year":"2013","unstructured":"Gutmann DH, McLellan MD, Hussain I et al (2013) Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res 23:431\u2013439. https:\/\/doi.org\/10.1101\/gr.142604.112","journal-title":"Genome Res"},{"key":"5835_CR7","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology: Pediatric Central Nervous System Cancers. Version 1.2026. https:\/\/www.nccn.org\/guidelines\/category_1. Accessed 30 May 2026"},{"key":"5835_CR8","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2026. https:\/\/www.nccn.org\/guidelines\/category_1. Accessed 30 May 2026"},{"key":"5835_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee A, Jakacki RI, Onar-Thomas A et al (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium study. Neuro Oncol 19:1135\u20131144. https:\/\/doi.org\/10.1093\/neuonc\/now282","journal-title":"Neuro Oncol"},{"key":"5835_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T et al (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011\u20131022. https:\/\/doi.org\/10.1016\/S1470-2045(19)30277-3","journal-title":"Lancet Oncol"},{"key":"5835_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML et al (2023) Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389:1108\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa2303815","journal-title":"N Engl J Med"},{"key":"5835_CR12","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","volume":"22","author":"NJ Ullrich","year":"2020","unstructured":"Ullrich NJ, Prabhu SP, Reddy AT et al (2020) A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol 22:1527\u20131535. https:\/\/doi.org\/10.1093\/neuonc\/noaa071","journal-title":"Neuro Oncol"},{"key":"5835_CR13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/neuonc\/noad033","volume":"25","author":"CG Romo","year":"2023","unstructured":"Romo CG, Piotrowski AF, Campian JL et al (2023) Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Neuro Oncol 25:1474\u20131486. https:\/\/doi.org\/10.1093\/neuonc\/noad033","journal-title":"Neuro Oncol"},{"key":"5835_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00401-022-02513-5","volume":"145","author":"PJ Cimino","year":"2023","unstructured":"Cimino PJ, Ketchum C, Turakulov R et al (2023) Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathol 145:71\u201382. https:\/\/doi.org\/10.1007\/s00401-022-02513-5","journal-title":"Acta Neuropathol"},{"key":"5835_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/jcpt.12378","volume":"41","author":"M Ameratunga","year":"2016","unstructured":"Ameratunga M, McArthur G, Gan H, Cher L (2016) Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma. J Clin Pharm Ther 41:357\u2013359. https:\/\/doi.org\/10.1111\/jcpt.12378","journal-title":"J Clin Pharm Ther"},{"key":"5835_CR16","doi-asserted-by":"publisher","first-page":"e13562","DOI":"10.1200\/JCO.2019.37.15_suppl.e13562","volume":"37","author":"CG Romo","year":"2019","unstructured":"Romo CG, Slobogean BL, Blair LK, Blakeley JO (2019) Trametinib for aggressive gliomas in adults with neurofibromatosis type 1. J Clin Oncol 37:e13562. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e13562","journal-title":"J Clin Oncol"},{"key":"5835_CR17","doi-asserted-by":"publisher","first-page":"v168","DOI":"10.1093\/neuonc\/noaf201.0665","volume":"27","author":"C Boldig","year":"2025","unstructured":"Boldig C, Elzaafarany O, Sun Y et al (2025) DDDR-28. Selumetinib in NF1-associated high-grade astrocytoma with piloid features. Neuro Oncol 27:v168. https:\/\/doi.org\/10.1093\/neuonc\/noaf201.0665","journal-title":"Neuro Oncol"},{"key":"5835_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00381-025-06864-8","volume":"41","author":"B Dion","year":"2025","unstructured":"Dion B, Sathyakumar S, Silverman J et al (2025) Sustained response to trametinib in an adult patient with neurofibromatosis type 1 and high-grade glioma. Childs Nerv Syst 41:202. https:\/\/doi.org\/10.1007\/s00381-025-06864-8","journal-title":"Childs Nerv Syst"},{"key":"5835_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1159\/000509773","volume":"13","author":"G Awada","year":"2020","unstructured":"Awada G, Serruys D, Schwarze JK et al (2020) Durable complete response of a recurrent mesencephalic glioblastoma treated with trametinib and low-dose dabrafenib in a patient with neurofibromatosis type 1. Case Rep Oncol 13:1031\u20131036. https:\/\/doi.org\/10.1159\/000509773","journal-title":"Case Rep Oncol"},{"key":"5835_CR20","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-12-0334","volume":"72","author":"WL See","year":"2012","unstructured":"See WL, Tan IL, Mukherjee J et al (2012) Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res 72:3350\u20133359. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0334","journal-title":"Cancer Res"},{"key":"5835_CR21","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.3390\/ijms26146875","volume":"26","author":"AS Levy","year":"2025","unstructured":"Levy AS, Bryant J-P, Matichak D et al (2025) MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions. Int J Mol Sci 26:6875. https:\/\/doi.org\/10.3390\/ijms26146875","journal-title":"Int J Mol Sci"},{"key":"5835_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ijc.31052","volume":"142","author":"MC De Gooijer","year":"2018","unstructured":"De Gooijer MC, Zhang P, Weijer R et al (2018) The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer 142:381\u2013391. https:\/\/doi.org\/10.1002\/ijc.31052","journal-title":"Int J Cancer"},{"key":"5835_CR23","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1535-7163.MCT-23-0510","volume":"23","author":"M Ioannou","year":"2024","unstructured":"Ioannou M, Lalwani K, Ayanlaja AA et al (2024) MEK inhibition enhances the antitumor effect of radiotherapy in NF1-deficient glioblastoma. Mol Cancer Ther 23:1261\u20131272. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0510","journal-title":"Mol Cancer Ther"},{"key":"5835_CR24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","volume":"29","author":"Y Balagula","year":"2011","unstructured":"Balagula Y, Barth Huston K, Busam KJ et al (2011) Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 29:1114\u20131121. https:\/\/doi.org\/10.1007\/s10637-010-9567-3","journal-title":"Invest New Drugs"},{"key":"5835_CR25","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu RI, Mahabadi AA, Michel L et al (2019) Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open 2:e198890. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.8890","journal-title":"JAMA Netw Open"},{"key":"5835_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/cancers15010141","volume":"15","author":"M Garutti","year":"2022","unstructured":"Garutti M, Bergnach M, Polesel J et al (2022) BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers 15:141. https:\/\/doi.org\/10.3390\/cancers15010141","journal-title":"Cancers"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05835-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:13Z","timestamp":1792683973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05835-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["5835"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05835-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"6 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was performed in line with the principles of the Declaration of Helsinki and was conducted under The University of Texas MD Anderson Cancer Center Institutional Review Board-approved protocol 2012\u2009\u2212\u20090441.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; only deidentified aggregate clinical data and deidentified imaging are presented.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived for this retrospective review.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30"}}